Ivacaftor
Olfactory Disorder
University of California, Los AngelesSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Olfactory Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Gonadotropin-Releasing Hormone Nelly Pitteloud | Phase 2/3 | B |
Gnrh Nelly Pitteloud | Phase 2/3 | B |
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION Nelly Pitteloud | Phase 2/3 | B |
ELEXACAFTOR University of California, Los Angeles | D | |
Tezacaftor University of California, Los Angeles | D | |
Cyr-064 University of Nebraska | Phase 1 | NR |
Same molecule, other indications
Ivacaftor is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →